Drugs / Simotinib
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01772732 | Dec 2012 → Dec 2015 | non-small cell lung carcinoma | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT01469910 | Sep 2011 → Jun 2012 | — | Jiangsu Simcere Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Simotinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01469910 ↗ |
| Known as | Sim-6802 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545235 ↗ |
| Action | Inhibit | “a novel EGFR tyrosine kinase inhibitor” PMID 31191007 ↗ May 2019 |
| Modality | Small molecule | “a novel EGFR tyrosine kinase inhibitor” PMID 31191007 ↗ May 2019 |
| Target | EGFR | “a novel EGFR tyrosine kinase inhibitor” PMID 31191007 ↗ May 2019 |